Trial · NCT03906448
FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma
NCT03906448, Phase 2, Terminated, University of Florida; results first posted 2021-09-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma. Trials, record NCT03906448. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03906448
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma
- NCT number
- NCT03906448
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- University of Florida
- Conditions
- Astrocytoma, Grade II, Astrocytoma, Grade III
- Interventions
- TTFields with adjuvant temozolomide
- First posted
- 2019-04-08
- Last updated
- 2021-09-23
- Results first posted
- 2021-09-23
- Limitations and caveats
This multicenter center study was terminated early by mutual decision between the Study Chair/IDE Sponsor and Novocure; therefore, statistical analysis of the 1 participant in the intervention arm was not done.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival | Up to 2 years | Frequency of overall survival in study participants. 2 years of active treatment, lifelong survival follow-up. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival | Up to 2 years | This multicenter center study was terminated early by mutual decision between the Study Chair/IDE Sponsor and Novocure; therefore, statistical analysis of the 1 participant in the intervention arm was not done. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Astrocytoma Patients | 1 | |
| Overall Study | STARTED | Control Arm | 0 | |
| Overall Study | COMPLETED | Astrocytoma Patients | 1 | |
| Overall Study | COMPLETED | Control Arm | 0 | |
| Overall Study | NOT COMPLETED | Astrocytoma Patients | 0 | |
| Overall Study | NOT COMPLETED | Control Arm | 0 |
Source ClinicalTrials.gov
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Rash | Skin and subcutaneous tissue disorders | Astrocytoma Patients | 1 | 1 | 1 |
| other | Rash | Skin and subcutaneous tissue disorders | Control Arm | 0 | 0 | 0 |
| other | Platelet Count Decreased | Blood and lymphatic system disorders | Astrocytoma Patients | 1 | 1 | 1 |
| other | Platelet Count Decreased | Blood and lymphatic system disorders | Control Arm | 0 | 0 | 0 |
| other | Syncope | Cardiac disorders | Astrocytoma Patients | 1 | 1 | 2 |
| other | Syncope | Cardiac disorders | Control Arm | 0 | 0 | 0 |
| other | Nausea | Gastrointestinal disorders | Astrocytoma Patients | 1 | 1 | 1 |
| other | Nausea | Gastrointestinal disorders | Control Arm | 0 | 0 | 0 |
| other | Reactive Dermatitis | Skin and subcutaneous tissue disorders | Astrocytoma Patients | 1 | 1 | 1 |
| other | Reactive Dermatitis | Skin and subcutaneous tissue disorders | Control Arm | 0 | 0 | 0 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Astrocytoma Patients | 1 | 1 |
| Total, all-cause mortality | Control Arm | 0 | 0 |
| Total, other adverse events | Astrocytoma Patients | 1 | 1 |
| Total, other adverse events | Control Arm | 0 | 0 |
| Total, serious adverse events | Astrocytoma Patients | 1 | 1 |
| Total, serious adverse events | Control Arm | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03906448
GET https://conductscience.org/api/trials/v1/NCT03906448/registered